Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update
Aims Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods In this prospective trial,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2025-12-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450923.2025.2516994 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|